首页> 外文期刊>Substance Abuse Treatment, Prevention, and Policy >Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis
【24h】

Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis

机译:注入药物的人群中与HCV测试相关的患病率和高风险行为:系统审查和荟萃分析

获取原文
       

摘要

Hepatitis C diagnosis could be a gateway to behavioral change and subsequent decline in transmission among people who inject drugs (PWIDs). We assessed the association between the social determinants of PWID, their risk behaviors and hepatitis C testing. We searched for studies in English published before May 1, 2020, on PubMed, Scopus, Cochrane, and Web of Science to identify primary studies on the factors associated with hepatitis C virus (HCV) testing among PWID. After reviewing for study duplicates, the full-text of selected articles were assessed for eligibility using Population, Intervention, Comparator, Outcomes (PICO) criteria. i) population: individuals who report injecting drugs; ii) intervention: HCV testing in the past year; iii) comparator: PWIDs who did not have an HCV test; iv) outcome: HCV testing among PWIDs and v) study type: cross-sectional, cohort, and case-control studies. Two independent reviewers (author BA and AB) chose the references in a two-phased monitoring process. The authors gathered data from selected papers, including the surname of the first author, publication date, participant demographic data (age, sex, and level of education) and other characteristics like previous HCV testing, past treatment attempts, duration of injecting drug use and condomless sex. We used fixed and random-effects meta-analysis models to estimate the pooled prevalence, pooled odds ratio (OR), and 95% confidence intervals. The data were analyzed using Stata 12.0 software. After a detailed assessment of over 12,000 articles, a total of 16 studies containing 38,952 participants met the eligibility criteria. Our findings showed a pooled prevalence rate of 61.01% (95% CI, 34.65–84.32%) for recent HCV testing among PWIDs. Being female (OR?=?1.69, 95%CI?=?1.13, 2.26), aged ?30?years, (OR?=?2.61, 95%CI?=?1.66–3.56) having past treatment attempt (OR?=?2.24, 95%CI?=?1.80–2.68), and reporting a previous test (OR?=?2.03, 95%CI?=?1.23–2.82). were significantly associated with having a recent HCV test.,,. Finding of present study was that unprotected sex had a negative association with HCV testing. Those PWIDs who had unprotected sex were 0.56 times less likely to have completed HCV testing during last year (OR?=?0.56, 95%CI?=?0.33–0.78). Prevention programs that address age??30?years, being female, past treatment attempt, previous testing of safe sexual practices, are strongly recommended to prioritize HCV risk reduction strategies.
机译:丙型肝炎诊断可能是行为变化的门户,并在注射药物(PWIDS)的人中随后的传播下降。我们评估了PWID,风险行为和丙型肝炎的社会决定因素之间的关联。我们在2020年5月1日之前搜索了英语学习,在PubMed,Scopus,Cochrane和科学网上,以确定对PWID之间与丙型肝炎病毒(HCV)测试相关的因素的初步研究。在审查研究重复后,使用人口,干预,比较者,结果(PICO)标准评估所选文章的全文。 i)人口:报告注射毒品的个人; ii)干预:过去一年中的HCV测试; III)比较器:没有HCV测试的PWID; IV)结果:PWIDS和V之间的HCV测试)研究类型:横截面,群组和病例对照研究。两个独立审稿人(作者BA和AB)选择了双相监测过程中的参考。作者收集了所选论文的数据,包括第一作者的姓氏,出版日期,参与人口统计数据(年龄,性别和教育程度)和以前的HCV测试等特征,过去的治疗尝试,注射药物使用的持续时间和有道疾人的性。我们使用固定和随机效应元分析模型来估算汇集的流行率,汇集赔率比(或)和95%的置信区间。使用Stata 12.0软件分析数据。经过12,000多篇文章的详细评估后,共有16项含有38,952名参与者的研究符合了资格标准。我们的研究结果表明,对于最近的PWID,近期HCV测试汇总患有61.01%(95%CI,34.65-84.32%)。是女性(或?=?1.69,95%CI?=?1.13,2.26),年龄>?30?年,(或?=?2.61,95%CI?= 1.66-3.56)过去治疗尝试(或?=?2.24,95%ci?=?1.80-2.68),并报告先前的测试(或?=?2.03,95%ci?=?1.23-2.82)。与最近的HCV测试有显着相关。,。寻找本研究是,无保护的性别与HCV测试具有负关联。在去年(或?= 0.56,95%CI = = 0.33-0.78),在去年(或?= 0.56,95%CI),那些未受保护性别的性别的皮脂患者的性别少0.56倍。解决年龄的预防计划?>?30?多年,是女性,过去的治疗尝试,以前的安全性行为测试,强烈建议优先考虑HCV风险降低策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号